title: Oral therapy approved for chronic HCV infection of all genotypes.
authors.forename: Kate
authors.initials: K
authors.lastname: Traynor
mesh_terms: D000284:Administration, Oral; D000998:Antiviral Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D002219:Carbamates / Q000008:administration & dosage* / Q000493:pharmacokinetics; D017277:Drug Approval; D004338:Drug Combinations; D005838:Genotype; D019698:Hepatitis C, Chronic / Q000188:drug therapy* / Q000378:metabolism; D006576:Heterocyclic Compounds, 4 or More Rings / Q000008:administration & dosage* / Q000493:pharmacokinetics; D006801:Humans; D012254:Ribavirin / Q000008:administration & dosage / Q000493:pharmacokinetics; D000069474:Sofosbuvir / Q000008:administration & dosage* / Q000493:pharmacokinetics
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D004338:Drug Combinations; D006576:Heterocyclic Compounds, 4 or More Rings; C000611331:sofosbuvir-velpatasvir drug combination; D012254:Ribavirin; D000069474:Sofosbuvir